Shanghai-based Abbisko Therapeutics has secured $70 million in a Series C round of financing led by Singaporean state-owned investment firm Temasek, bringing the total capital raised by the Chinese biopharma firm to $140 million.
Existing investors Singapore’s GIC, Chinese venture capital firm Qiming Venture Partners, and Jianxin Capital, a fund management platform of China’s CCB International, participated in the investment.
